{
  "directed": true,
  "graph": {
    "annotation_list": {
      "PublicationStatus": [
        "Published"
      ],
      "PublicationType": [
        "Communication"
      ],
      "Section": [
        "Full Text"
      ],
      "Study": [
        "in silico"
      ]
    },
    "annotation_pattern": {},
    "annotation_url": {
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20190128.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20190128.belanno",
      "Species": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/species-taxonomy-id/species-taxonomy-id-20170511.belanno"
    },
    "document_metadata": {
      "authors": "Geena Mariya Jose",
      "contact": "geena.mariya.jose@causalitybiomodels.com",
      "copyright": "Copyright © 2020 Fraunhofer Institute SCAI, All rights reserved",
      "description": "COVID Knowledge Curation project",
      "licenses": "Private Ownership to Fraunhofer Institute SCAI",
      "name": "32147628.bel",
      "version": "2.0.0"
    },
    "namespace_pattern": {
      "FIXME": ".*",
      "NCBIGENE": ".*",
      "PUBCHEM": "^\\d+$"
    },
    "namespace_url": {
      "CHEBI": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/chebi/chebi-20190708.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20200407.belns",
      "DRUGBANK": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/drugbank/drugbank-20180906.belns",
      "EFO": "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns",
      "GO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go/go-20180109.belns",
      "GOBP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go-biological-process/go-biological-process-20190128.belns",
      "HGNC": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc/hgnc-20190708.belns",
      "MESH": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh/mesh-names-20181007.belns",
      "MESHPP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-processes/mesh-processes-20190128.belns",
      "TAX": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/ncbi-taxonomy/ncbi-taxonomy-20200322.belns"
    },
    "path": "32147628.bel",
    "pybel_version": "0.14.6"
  },
  "links": [
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "The fifth edition of the Guidelines recommends antivirals including IFN-α, lopinavir/ritonavir, and ribavirin for treatment of COVID-19 (3).",
      "key": "2fcfce41b63d0b50574270a1775e9a93",
      "line": 96,
      "relation": "decreases",
      "source": 45,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "IFN-α is a broad-spectrum antiviral that is usually used to treat hepatitis, though it is reported to inhibit SARS-CoV reproduction in vitro (4).",
      "key": "5b12d82207b2e7261fcb1f9793e8dbaf",
      "line": 106,
      "relation": "decreases",
      "source": 45,
      "target": 74
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "IFN-α is a broad-spectrum antiviral that is usually used to treat hepatitis, though it is reported to inhibit SARS-CoV reproduction in vitro (4).",
      "key": "1271f4bb4e716fe4cab3c884780e1910",
      "line": 107,
      "relation": "decreases",
      "source": 45,
      "target": 57
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "60a31f532c64b87850b1f4a1b79f29f4",
      "line": 283,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 17
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "f3a77e6ca6e3f1c4a0d7787eb43d96ae",
      "line": 284,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 23
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "955caaa7cc1f06228f9cb8ea30cc7750",
      "line": 285,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 7
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "f6542f6f61361b73d6e77094601a88e0",
      "line": 286,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 5
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "9c61c61fd2dc6c1cfa1778b9bfea237f",
      "line": 287,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 24
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "89623d84d0b4fb8931f14e5d70b417ea",
      "line": 288,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 15
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "1e48dfceb9220fa75ab19bfcae56ea34",
      "line": 289,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 52
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "321d2d779dca6b766530079b13b3a6ba",
      "line": 290,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 31
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "2e0cd6e23c2c30de89ca719a37ea245a",
      "line": 291,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 4
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "88f4ca9728969806b86313208021dab1",
      "line": 292,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 6
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "504d4818f25ea7e75468d7de6695d023",
      "line": 293,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 13
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "0c3a6b7d391409506a505ed7fb6fbd07",
      "line": 294,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 28
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "064264385be67cd35c7fb06557441831",
      "line": 295,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 29
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "6f69b7737d9f1756c08a914c41e83570",
      "line": 296,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 19
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "68ccbb39b0613617a52a8c44bd448c92",
      "line": 297,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 49
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "b6c37dff165f42ded83aa5f433f18961",
      "line": 298,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 1
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "ed156ff1069b840d17a0b01ef7fc8195",
      "line": 299,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 8
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "3ccaa2aa7323204c360bb3ff30c13107",
      "line": 300,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 11
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "cc94dcf30d6adde42214d95eb97c46a3",
      "line": 301,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 2
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "4d48b0fb093f20880269d700e2236c79",
      "line": 302,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 3
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "68721074ccd19a338adb47c701403673",
      "line": 303,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 12
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "92222ccb8d1c85f3eac2e9c7c4edf7be",
      "line": 304,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 30
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "c5a2b3bd54006a2b4e27b1a14c3643cd",
      "line": 305,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 27
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "6abbd3d19c65c434ef971d9cce54dfb6",
      "line": 306,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 46
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "bd1304fcaf2e98039f0b92c265222c8b",
      "line": 307,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 0
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "18251e91258d1c8d93bd9367380b20bc",
      "line": 308,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 37
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "03182fb6921a7b4bf1d13bece6541d94",
      "line": 309,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 39
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "3a420a6503ecdd939b9d82cc36da3e49",
      "line": 310,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 40
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "The fifth edition of the Guidelines recommends antivirals including IFN-α, lopinavir/ritonavir, and ribavirin for treatment of COVID-19 (3).",
      "key": "576b797cca173af9f51618ba98282eef",
      "line": 97,
      "relation": "decreases",
      "source": 18,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Lopinavir/ritonavir is a medication for the human immunodeficiency virus (HIV) used in combination with other medications to treat adults and children over 14 days of age who are infected with HIV-1 (5).",
      "key": "68ca7c80f58b92b3f78217e119fb442f",
      "line": 110,
      "relation": "decreases",
      "source": 18,
      "target": 54
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Chu et al. found that lopinavir/ ritonavir has anti-SARS-CoV activity in vitro and in clinical studies (6).",
      "key": "3a8b47fa2eee54b1917d14a748c83e0b",
      "line": 114,
      "relation": "decreases",
      "source": 18,
      "target": 57
    },
    {
      "key": "3287546b797ddabe3ae2f7e2fe7b50d9",
      "relation": "partOf",
      "source": 18,
      "target": 64
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "f4063df69ab3c6c2c30b8a26d3c06eda",
      "line": 166,
      "relation": "decreases",
      "source": 18,
      "target": 56
    },
    {
      "key": "f18924ce25341d06b4bb377528fcb9a5",
      "relation": "partOf",
      "source": 18,
      "target": 65
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "The fifth edition of the Guidelines recommends antivirals including IFN-α, lopinavir/ritonavir, and ribavirin for treatment of COVID-19 (3).",
      "key": "fdc3032daa76e0be2b60589fa793f2bd",
      "line": 98,
      "relation": "decreases",
      "source": 22,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Lopinavir/ritonavir is a medication for the human immunodeficiency virus (HIV) used in combination with other medications to treat adults and children over 14 days of age who are infected with HIV-1 (5).",
      "key": "298b7e65abc2edc1be0e81b233197dff",
      "line": 111,
      "relation": "decreases",
      "source": 22,
      "target": 54
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Chu et al. found that lopinavir/ ritonavir has anti-SARS-CoV activity in vitro and in clinical studies (6).",
      "key": "bcdb0f88db740b4d9461835aac2693c5",
      "line": 115,
      "relation": "decreases",
      "source": 22,
      "target": 57
    },
    {
      "key": "5d9ea4f0ac4b8d8f933d0dbc58bf701b",
      "relation": "partOf",
      "source": 22,
      "target": 66
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "021da882f096511c5b6fcfe6510450e9",
      "line": 168,
      "relation": "decreases",
      "source": 22,
      "target": 56
    },
    {
      "key": "6a69b9c011b905760ffd20c4fc045a23",
      "relation": "partOf",
      "source": 22,
      "target": 65
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "The fifth edition of the Guidelines recommends antivirals including IFN-α, lopinavir/ritonavir, and ribavirin for treatment of COVID-19 (3).",
      "key": "251f9e05e637d370263fd2ee70d31dd3",
      "line": 99,
      "relation": "decreases",
      "source": 21,
      "target": 71
    },
    {
      "key": "53a451658ada31066307fe3ea89a9d25",
      "relation": "partOf",
      "source": 21,
      "target": 64
    },
    {
      "key": "c4fd90df430c781c65d418c080e626be",
      "relation": "partOf",
      "source": 21,
      "target": 66
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Ribavirin  is  a  nucleoside  analogue  with  a  broad-spectrum  of  antiviral  effects.  A  study  compared  111  patients  with  severe  acute  respiratory  syndrome  (SARS)  treated  with  ribavirin  monotherapy  and  41  patients  with  SARS  treated  with  lopinavir/ritonavir and ribavirin; patients treated with the combined therapy  had  a  lower  risk  of  acute  respiratory  distress  syndrome  (ARDS)  and  death  (6).",
      "key": "b6c8c2d7754bc62b5037a30d89eebf00",
      "line": 215,
      "object": {
        "modifier": "Activity"
      },
      "relation": "association",
      "source": 21,
      "target": 32
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Ribavirin  is  a  nucleoside  analogue  with  a  broad-spectrum  of  antiviral  effects.  A  study  compared  111  patients  with  severe  acute  respiratory  syndrome  (SARS)  treated  with  ribavirin  monotherapy  and  41  patients  with  SARS  treated  with  lopinavir/ritonavir and ribavirin; patients treated with the combined therapy  had  a  lower  risk  of  acute  respiratory  distress  syndrome  (ARDS)  and  death  (6).",
      "key": "e608a347e7dd0b2e56305af831e2a032",
      "line": 216,
      "relation": "decreases",
      "source": 21,
      "target": 76
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Ribavirin  is  a  nucleoside  analogue  with  a  broad-spectrum  of  antiviral  effects.  A  study  compared  111  patients  with  severe  acute  respiratory  syndrome  (SARS)  treated  with  ribavirin  monotherapy  and  41  patients  with  SARS  treated  with  lopinavir/ritonavir and ribavirin; patients treated with the combined therapy  had  a  lower  risk  of  acute  respiratory  distress  syndrome  (ARDS)  and  death  (6).",
      "key": "d06dc2fbc49d764ae591f134a89d9e14",
      "line": 217,
      "relation": "decreases",
      "source": 21,
      "target": 88
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Chloroquine phosphate and arbidol are included in the sixth edition of the Guidelines based on the preliminary outcomes of clinical studies (2).",
      "key": "8e1f39427ad3a21ce638b08871a67f91",
      "line": 102,
      "relation": "decreases",
      "source": 53,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Chloroquine phosphate and arbidol are included in the sixth edition of the Guidelines based on the preliminary outcomes of clinical studies (2).",
      "key": "207c6436575c8a0ed3d02bd13e905e0b",
      "line": 103,
      "relation": "decreases",
      "source": 43,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A study has revealed that arbidol can effectively inhibit SARS-CoV-2 infection at a concentration of 10-30 μM in vitro (9).",
      "key": "92b57f7de456cac4c2662e2658aac2fc",
      "line": 127,
      "relation": "decreases",
      "source": 43,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "IFN-α is a broad-spectrum antiviral that is usually used  to  treat  hepatitis,  though  it  is  reported  to  inhibit  SARS-CoV reproduction in vitro (4).",
      "key": "2b873fcb171044f8b0cbcfb3022898d2",
      "line": 205,
      "relation": "negativeCorrelation",
      "source": 74,
      "target": 26
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A study compared 111 patients with severe acute respiratory syndrome (SARS) treated with ribavirin monotherapy and 41 patients with SARS treated with lopinavir/ ritonavir and ribavirin; patients treated with the combined therapy had a lower risk of acute respiratory distress syndrome (ARDS) and death (6).",
      "key": "4036eddb79bf2bf1704e6b94fd2b2999",
      "line": 119,
      "relation": "decreases",
      "source": 64,
      "target": 72
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A study compared 111 patients with severe acute respiratory syndrome (SARS) treated with ribavirin monotherapy and 41 patients with SARS treated with lopinavir/ ritonavir and ribavirin; patients treated with the combined therapy had a lower risk of acute respiratory distress syndrome (ARDS) and death (6).",
      "key": "2ff9d788e1c7722e1d18aa8daa5fbf12",
      "line": 120,
      "relation": "decreases",
      "source": 66,
      "target": 72
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Chloroquine was found to block SARS-CoV-2 infection at low micromolar concentration, with a half-maximal effective concentration (EC50) of 1.13 μM and a half-cytotoxic concentration (CC50) greater than 100 μM (8).",
      "key": "9f3bce1877254b621ae351022c10b845",
      "line": 124,
      "relation": "decreases",
      "source": 9,
      "target": 57
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Chloroquine  is  a  widely used antimalarial that was found to be a potential broad-spectrum  antiviral  in  2006  (7).  Chloroquine  was  found  to  block  SARS-CoV-2  infection  at  low-micromolar concentration, with a half-maximal effective concentration  (EC50) of 1.13 μM and a half-cytotoxic concentration  (CC50) greater than 100 μM (8).",
      "key": "0bc009d61b09eb0d67fa9f1bd6a5b26b",
      "line": 222,
      "relation": "isA",
      "source": 9,
      "target": 36
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Chloroquine  is  a  widely used antimalarial that was found to be a potential broad-spectrum  antiviral  in  2006  (7).  Chloroquine  was  found  to  block  SARS-CoV-2  infection  at  low-micromolar concentration, with a half-maximal effective concentration  (EC50) of 1.13 μM and a half-cytotoxic concentration  (CC50) greater than 100 μM (8).",
      "key": "be3fe1927834a7fb86ea62120b7b5da3",
      "line": 223,
      "relation": "association",
      "source": 9,
      "subject": {
        "modifier": "Activity"
      },
      "target": 32
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Chloroquine  is  a  widely used antimalarial that was found to be a potential broad-spectrum  antiviral  in  2006  (7).  Chloroquine  was  found  to  block  SARS-CoV-2  infection  at  low-micromolar concentration, with a half-maximal effective concentration  (EC50) of 1.13 μM and a half-cytotoxic concentration  (CC50) greater than 100 μM (8).",
      "key": "638798decaff517e656761288ce657f7",
      "line": 224,
      "relation": "decreases",
      "source": 9,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir was approved for treatment of novel influenza on February 15, 2020 in China.",
      "key": "20a88b54154381bd605df695a2699d0b",
      "line": 130,
      "relation": "decreases",
      "source": 14,
      "target": 75
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "The preliminary results from a total of 80 patients (including the experimental group and the control group) indicated that favipiravir had more potent antiviral action than that of lopinavir/ritonavir (12).",
      "key": "d9299cdcb81857104398ed02f6fbbc0f",
      "line": 134,
      "relation": "decreases",
      "source": 14,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza  virus  activity,  favipiravir  is  capable  of  blocking  the  replication  of  flavi-,  alpha-,  filo-,  bunya-,  arena-, noro-, and other RNA viruses (10).",
      "key": "77c2fe144b0e389debab2803168c32c6",
      "line": 233,
      "relation": "decreases",
      "source": 14,
      "target": 34
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza  virus  activity,  favipiravir  is  capable  of  blocking  the  replication  of  flavi-,  alpha-,  filo-,  bunya-,  arena-, noro-, and other RNA viruses (10).",
      "key": "14141455e8ca5f57b4c6ac5b568ce3d4",
      "line": 234,
      "relation": "negativeCorrelation",
      "source": 14,
      "subject": {
        "modifier": "Activity"
      },
      "target": 77
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza  virus  activity,  favipiravir  is  capable  of  blocking  the  replication  of  flavi-,  alpha-,  filo-,  bunya-,  arena-, noro-, and other RNA viruses (10).",
      "key": "ad4277653505d79dd27d4353503001d9",
      "line": 235,
      "relation": "negativeCorrelation",
      "source": 14,
      "target": 83
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza  virus  activity,  favipiravir  is  capable  of  blocking  the  replication  of  flavi-,  alpha-,  filo-,  bunya-,  arena-, noro-, and other RNA viruses (10).",
      "key": "a614af4cb616acf1f902c98c0effa3ca",
      "line": 236,
      "relation": "negativeCorrelation",
      "source": 14,
      "target": 78
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza  virus  activity,  favipiravir  is  capable  of  blocking  the  replication  of  flavi-,  alpha-,  filo-,  bunya-,  arena-, noro-, and other RNA viruses (10).",
      "key": "a9c32be1151d965ed8a35eabbb84afb4",
      "line": 237,
      "relation": "negativeCorrelation",
      "source": 14,
      "target": 82
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza  virus  activity,  favipiravir  is  capable  of  blocking  the  replication  of  flavi-,  alpha-,  filo-,  bunya-,  arena-, noro-, and other RNA viruses (10).",
      "key": "08a94e01732f1d4ba2f4bb893cffa8cf",
      "line": 238,
      "relation": "negativeCorrelation",
      "source": 14,
      "target": 80
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza  virus  activity,  favipiravir  is  capable  of  blocking  the  replication  of  flavi-,  alpha-,  filo-,  bunya-,  arena-, noro-, and other RNA viruses (10).",
      "key": "d166ecd32dde34ee6437d134400ba9da",
      "line": 239,
      "relation": "negativeCorrelation",
      "source": 14,
      "target": 79
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza  virus  activity,  favipiravir  is  capable  of  blocking  the  replication  of  flavi-,  alpha-,  filo-,  bunya-,  arena-, noro-, and other RNA viruses (10).",
      "key": "d7c2e891dd93148dd88e9061b94cef5e",
      "line": 240,
      "relation": "negativeCorrelation",
      "source": 14,
      "target": 81
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza  virus  activity,  favipiravir  is  capable  of  blocking  the  replication  of  flavi-,  alpha-,  filo-,  bunya-,  arena-, noro-, and other RNA viruses (10).",
      "key": "791182abaf1b7323aaf9f11fa31c663d",
      "line": 241,
      "relation": "negativeCorrelation",
      "source": 14,
      "target": 85
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir  is  converted  into  an  active  phosphoribosylated  form  (favipiravir-RTP)  in  cells  and  is  recognized  as  a  substrate by viral RNA polymerase, thus inhibiting RNA polymerase activity (11).",
      "key": "1a55952fb77afce1aace2636c9593773",
      "line": 245,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 14,
      "target": 14
    },
    {
      "key": "e2a3a4fbf4b0d2b428a93252ba33cdc6",
      "relation": "partOf",
      "source": 14,
      "target": 63
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir  is  converted  into  an  active  phosphoribosylated  form  (favipiravir-RTP)  in  cells  and  is  recognized  as  a  substrate by viral RNA polymerase, thus inhibiting RNA polymerase activity (11).",
      "key": "0a04240b0a46e47123d2c56446489823",
      "line": 246,
      "relation": "increases",
      "source": 14,
      "subject": {
        "modifier": "Activity"
      },
      "target": 63
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Remdesivir is another potential drug for treatment of COVID-19.",
      "key": "9b19fcb187b02c537faaec9223bcc103",
      "line": 138,
      "relation": "decreases",
      "source": 42,
      "target": 71
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Wang et al. found that remdesivir potently  blocks  SARS-CoV-2  infection  at  low-micromolar  concentrations  and  has  a  high  selectivity  index (half-maximal effective concentration (EC50), 0.77 μM; half-cytotoxic concentration (CC50) > 100 μM; SI >  129.87)  (8).",
      "key": "37a3f3c4780cfd88e64af3a58292cbdf",
      "line": 263,
      "relation": "decreases",
      "source": 42,
      "target": 71
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Lung": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Animal experiments (13) indicated that remdesivir can effectively reduce the viral load in lung tissue of mice infected with MERSCoV, improve lung function, and alleviate pathological damage to lung tissue.",
      "key": "16ec2b82a9edd48af2124bfe437eb311",
      "line": 142,
      "relation": "decreases",
      "source": 42,
      "target": 55
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Wang et al. found that remdesivir potently blocks SARS-CoV-2 infection at low micromolar concentrations and has a high selectivity index (half-maximal effective concentration (EC50), 0.77 μM; half-cytotoxic concentration (CC50) > 100 μM; SI > 129.87) (8).",
      "key": "c4c43568d616c18611181fbfdbe1dcd2",
      "line": 146,
      "relation": "decreases",
      "source": 42,
      "target": 56
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "201b51540cc738b2288291b38e3b3f6f",
      "line": 169,
      "relation": "decreases",
      "source": 42,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Remdesivir  is  a  nucleoside  analogue  and  a  broad-spectrum  antiviral.  Animal  experiments  (13)  indicated  that  remdesivir  can  effectively  reduce  the  viral load in lung tissue of mice infected with MERS-CoV,  improve  lung  function,  and  alleviate  pathological  damage to lung tissue.",
      "key": "6098803bb5b010c905cc82f1fd7659a0",
      "line": 251,
      "relation": "isA",
      "source": 42,
      "target": 32
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Lung": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Remdesivir  is  a  nucleoside  analogue  and  a  broad-spectrum  antiviral.  Animal  experiments  (13)  indicated  that  remdesivir  can  effectively  reduce  the  viral load in lung tissue of mice infected with MERS-CoV,  improve  lung  function,  and  alleviate  pathological  damage to lung tissue.",
      "key": "336f4a67a505a7207f989a40fd94dd68",
      "line": 255,
      "relation": "decreases",
      "source": 42,
      "target": 86
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Lung": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Remdesivir  is  a  nucleoside  analogue  and  a  broad-spectrum  antiviral.  Animal  experiments  (13)  indicated  that  remdesivir  can  effectively  reduce  the  viral load in lung tissue of mice infected with MERS-CoV,  improve  lung  function,  and  alleviate  pathological  damage to lung tissue.",
      "key": "427dd8a598c82dca59dbc8e2931cde89",
      "line": 256,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 42,
      "target": 38
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Lung": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Remdesivir  is  a  nucleoside  analogue  and  a  broad-spectrum  antiviral.  Animal  experiments  (13)  indicated  that  remdesivir  can  effectively  reduce  the  viral load in lung tissue of mice infected with MERS-CoV,  improve  lung  function,  and  alleviate  pathological  damage to lung tissue.",
      "key": "1fc3510a030f3d8b2b36585d29be2932",
      "line": 257,
      "relation": "decreases",
      "source": 42,
      "target": 84
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "On February 4, 2020, researchers in China announced that darunavir inhibited SARS-CoV-2 infection in vitro (9).",
      "key": "7bf48f8b0621923bc6bb815894d07d03",
      "line": 149,
      "relation": "decreases",
      "source": 10,
      "target": 56
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "c0868dd1afc9490e2c880f917e5ef184",
      "line": 171,
      "relation": "decreases",
      "source": 10,
      "target": 56
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Cell experiments indicated that darunavir significantly inhibited viral replication at a concentration of 300 μM in vitro and that its inhibition efficiency was 280-fold that in the untreated group (9)",
      "key": "fbf4ba144985bc64dba5960054d362e1",
      "line": 152,
      "relation": "decreases",
      "source": 10,
      "target": 87
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Studies  have  also  revealed  some  other  drugs  may  have  potential  efficacy  in  treating  COVID-19.  One  is  darunavir,  which  is  a  second-generation  of  HIV-1  protease  inhibitor.  On  February  4,  2020,  researchers  in  China  announced  that  darunavir  inhibited  SARS-CoV-2  infection in  vitro  (9).  Cell  experiments  indicated  that  darunavir  significantly  inhibited  viral  replication  at  a  concentration of 300 μM in  vitro  and  that  its  inhibition  efficiency  was  280-fold  that  in  the  untreated  group  (9).",
      "key": "6ce954be300c8daabc43c68314e745f0",
      "line": 266,
      "relation": "isA",
      "source": 10,
      "target": 33
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Studies  have  also  revealed  some  other  drugs  may  have  potential  efficacy  in  treating  COVID-19.  One  is  darunavir,  which  is  a  second-generation  of  HIV-1  protease  inhibitor.  On  February  4,  2020,  researchers  in  China  announced  that  darunavir  inhibited  SARS-CoV-2  infection in  vitro  (9).  Cell  experiments  indicated  that  darunavir  significantly  inhibited  viral  replication  at  a  concentration of 300 μM in  vitro  and  that  its  inhibition  efficiency  was  280-fold  that  in  the  untreated  group  (9).",
      "key": "ad8b14ff0c87189540952275a36abc18",
      "line": 267,
      "relation": "decreases",
      "source": 10,
      "target": 71
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Studies  have  also  revealed  some  other  drugs  may  have  potential  efficacy  in  treating  COVID-19.  One  is  darunavir,  which  is  a  second-generation  of  HIV-1  protease  inhibitor.  On  February  4,  2020,  researchers  in  China  announced  that  darunavir  inhibited  SARS-CoV-2  infection in  vitro  (9).  Cell  experiments  indicated  that  darunavir  significantly  inhibited  viral  replication  at  a  concentration of 300 μM in  vitro  and  that  its  inhibition  efficiency  was  280-fold  that  in  the  untreated  group  (9).",
      "key": "64ee7f2a57fd12d8d465a266f7010211",
      "line": 268,
      "relation": "decreases",
      "source": 10,
      "target": 62
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Other potential drugs include type II transmembrane serine protease (TMSPSS2) inhibitors and BCR-ABL kinase inhibitor imatinib.",
      "key": "2143a1c57c3914e84b501b347c1f76d8",
      "line": 155,
      "relation": "decreases",
      "source": 16,
      "target": 69
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Other  potential  drugs  include  type  II  transmembrane  serine protease (TMSPSS2) inhibitors and BCR-ABL kinase  inhibitor  imatinib.",
      "key": "81113f0e239a4e86455e81a79a99f240",
      "line": 271,
      "relation": "decreases",
      "source": 16,
      "target": 69
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Other potential drugs include type II transmembrane serine protease (TMSPSS2) inhibitors and BCR-ABL kinase inhibitor imatinib.",
      "key": "3c8505a043c776009789bf7e1f32a041",
      "line": 156,
      "relation": "decreases",
      "source": 16,
      "target": 67
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Other potential drugs include type II transmembrane serine protease (TMSPSS2) inhibitors and BCR-ABL kinase inhibitor imatinib.",
      "key": "ef6d66cd06b602b413769382a1b3eba9",
      "line": 157,
      "relation": "decreases",
      "source": 16,
      "target": 56
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Imatinib has anticoronal activity primarily because it inhibits the fusion of virions with the endosomal membrane (18).",
      "key": "e7bbd660c9d228af0c0bbe4ecd4508b2",
      "line": 160,
      "relation": "decreases",
      "source": 16,
      "target": 59
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Other  potential  drugs  include  type  II  transmembrane  serine protease (TMSPSS2) inhibitors and BCR-ABL kinase  inhibitor  imatinib.",
      "key": "4937357af6b4cd43fc9720e7daeff0cc",
      "line": 272,
      "relation": "decreases",
      "source": 16,
      "target": 70
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Imatinib  has  anti-coronal activity primarily because it inhibits the fusion of virions with the endosomal membrane (18).",
      "key": "35f3f8e7e3bd105c0c9173f675aba777",
      "line": 279,
      "relation": "decreases",
      "source": 16,
      "target": 60
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Hoffmann  et  al.  indicated  that  SARS-CoV-2  uses  the  SARS-CoV  receptor,  ACE2,  and the cellular protease TMPRSS2 to enter target cells.",
      "key": "ba886db0dae4cdedf8f8839fbeb2d85b",
      "line": 276,
      "relation": "association",
      "source": 69,
      "target": 58
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "09214705fe0098568c50db7cc634b131",
      "line": 164,
      "relation": "decreases",
      "source": 17,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "a5ef3ab3693407c0f046cb0caffce50c",
      "line": 283,
      "relation": "negativeCorrelation",
      "source": 17,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "3b4f6bb76b670da5badb1366b159e6fb",
      "line": 165,
      "relation": "decreases",
      "source": 23,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "de9e58067301e0357dcb14641b43a374",
      "line": 284,
      "relation": "negativeCorrelation",
      "source": 23,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "874a95fbf99ba3f393989bb45c903400",
      "line": 167,
      "relation": "decreases",
      "source": 7,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "1fb27c772b8795d75856cb888ea79a2f",
      "line": 285,
      "relation": "negativeCorrelation",
      "source": 7,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "2b25fd222af1aa40449d13123142a44b",
      "line": 170,
      "relation": "decreases",
      "source": 5,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "cc1de560b82fbaf81d25b0be55890027",
      "line": 286,
      "relation": "negativeCorrelation",
      "source": 5,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "4d18ae8224130b3a03fae5fa0f5db9ca",
      "line": 172,
      "relation": "decreases",
      "source": 24,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "437732706b4c25dd6c45edfaab75352d",
      "line": 287,
      "relation": "negativeCorrelation",
      "source": 24,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "b32224036343f7f28ac675d30b2dd58e",
      "line": 173,
      "relation": "decreases",
      "source": 15,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "6652fd2d2dea99f5c4e89a91aff167eb",
      "line": 288,
      "relation": "negativeCorrelation",
      "source": 15,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "2dd388dab9173dc9436eb856a2457f0e",
      "line": 174,
      "relation": "decreases",
      "source": 52,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "db0d48c56cd48b4d2beeab664985e9f6",
      "line": 289,
      "relation": "negativeCorrelation",
      "source": 52,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "b41ecca968bd140fd7f8c58f74d4005c",
      "line": 175,
      "relation": "decreases",
      "source": 51,
      "target": 56
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "33e91bc922c31a01526e746cd62364c6",
      "line": 176,
      "relation": "decreases",
      "source": 4,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "b709a09b62f509d7e9e5cd2e2df2696a",
      "line": 291,
      "relation": "negativeCorrelation",
      "source": 4,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "7a83bde8f9c101698e5afb141a7baa1e",
      "line": 177,
      "relation": "decreases",
      "source": 6,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "560a3454ff10e58fc816663c316446f5",
      "line": 292,
      "relation": "negativeCorrelation",
      "source": 6,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "7f5d0a8c6c032c55b50a5048c28908c1",
      "line": 178,
      "relation": "decreases",
      "source": 13,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "10e59cd4ac16c06b02fd18252d1f9d7f",
      "line": 293,
      "relation": "negativeCorrelation",
      "source": 13,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "0b16c61e3da0bfd96ee2e7b10fcab62e",
      "line": 179,
      "relation": "decreases",
      "source": 47,
      "target": 56
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "33ad352aa0626bf59f920c2b3972ca41",
      "line": 180,
      "relation": "decreases",
      "source": 20,
      "target": 56
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "9606e0d05f7256e37fc5c1f313dd3273",
      "line": 181,
      "relation": "decreases",
      "source": 19,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "65c931475a9190ce53c67662c4b52c00",
      "line": 296,
      "relation": "negativeCorrelation",
      "source": 19,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "9460d06c07a5ecd1cc9afcc42c406c09",
      "line": 182,
      "relation": "decreases",
      "source": 49,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "ebcb75ffbadaf090b0edb454be346e27",
      "line": 297,
      "relation": "negativeCorrelation",
      "source": 49,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "8ca065ac0541a5c247a3879d0f6b4374",
      "line": 183,
      "relation": "decreases",
      "source": 48,
      "target": 56
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "61edf3fd21afd1ed71113381a1e0f8f1",
      "line": 184,
      "relation": "decreases",
      "source": 8,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "bd8dfac79e88afb4bfcfea5aa7be5173",
      "line": 299,
      "relation": "negativeCorrelation",
      "source": 8,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "ba569fe70ae580402d140ac005c16553",
      "line": 185,
      "relation": "decreases",
      "source": 11,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "41c46fb326e397b7e0e2117d83a95411",
      "line": 300,
      "relation": "negativeCorrelation",
      "source": 11,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "2b8fa9b7d2f0f1c56e5af29035c03e7b",
      "line": 186,
      "relation": "decreases",
      "source": 2,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "ed56d19eb4a5562da8f23c9378124613",
      "line": 301,
      "relation": "negativeCorrelation",
      "source": 2,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "25197bf1fcb2faf5c26fd42bf527c138",
      "line": 187,
      "relation": "decreases",
      "source": 3,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "03eb7b9ebf5edccb92f76b45f0f9ae43",
      "line": 302,
      "relation": "negativeCorrelation",
      "source": 3,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "d94770a948ed0af0496afef474b572cd",
      "line": 188,
      "relation": "decreases",
      "source": 12,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "6448283758bdd593508b42cd5d4e0bbd",
      "line": 303,
      "relation": "negativeCorrelation",
      "source": 12,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "e1990969f4c7f944b0e2afacc9b967d9",
      "line": 189,
      "relation": "decreases",
      "source": 41,
      "target": 56
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "62c69f5277233017a1b78a3c4f451b04",
      "line": 190,
      "relation": "decreases",
      "source": 44,
      "target": 56
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "427d33be9c317128c095443d7ff23f31",
      "line": 191,
      "relation": "decreases",
      "source": 46,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "b62a03ec00f771c25ce507cc69d3231b",
      "line": 306,
      "relation": "negativeCorrelation",
      "source": 46,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "e960975dce45f99ede6741c34387ff31",
      "line": 192,
      "relation": "decreases",
      "source": 0,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "961762fbdb11ddc7f103e4c7055ccfda",
      "line": 307,
      "relation": "negativeCorrelation",
      "source": 0,
      "target": 71
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Communication": true
        },
        "Section": {
          "Full Text": true
        },
        "Study": {
          "in silico": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin.",
      "key": "bbd077fa918f234834fc5b7fbcbbdbc5",
      "line": 193,
      "relation": "decreases",
      "source": 50,
      "target": 56
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "IFN-α is a broad-spectrum antiviral that is usually used  to  treat  hepatitis,  though  it  is  reported  to  inhibit  SARS-CoV reproduction in vitro (4).",
      "key": "d1310f42c67d0b65d7635691b1cac9c4",
      "line": 204,
      "relation": "isA",
      "source": 26,
      "target": 32
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "IFN-α is a broad-spectrum antiviral that is usually used  to  treat  hepatitis,  though  it  is  reported  to  inhibit  SARS-CoV reproduction in vitro (4).",
      "key": "a5ac51f4d7df868f881453461ab1b644",
      "line": 205,
      "relation": "negativeCorrelation",
      "source": 26,
      "target": 74
    },
    {
      "annotations": {
        "MeSHDisease": {
          "Severe Acute Respiratory Syndrome": true
        }
      },
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "IFN-α is a broad-spectrum antiviral that is usually used  to  treat  hepatitis,  though  it  is  reported  to  inhibit  SARS-CoV reproduction in vitro (4).",
      "key": "7e251f605f2ed15e53188486ff5f7f62",
      "line": 207,
      "relation": "decreases",
      "source": 26,
      "target": 61
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Ribavirin  is  a  nucleoside  analogue  with  a  broad-spectrum  of  antiviral  effects.  A  study  compared  111  patients  with  severe  acute  respiratory  syndrome  (SARS)  treated  with  ribavirin  monotherapy  and  41  patients  with  SARS  treated  with  lopinavir/ritonavir and ribavirin; patients treated with the combined therapy  had  a  lower  risk  of  acute  respiratory  distress  syndrome  (ARDS)  and  death  (6).",
      "key": "69888a1ea99558710f2b68bf2fd10250",
      "line": 215,
      "relation": "association",
      "source": 32,
      "subject": {
        "modifier": "Activity"
      },
      "target": 21
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Chloroquine  is  a  widely used antimalarial that was found to be a potential broad-spectrum  antiviral  in  2006  (7).  Chloroquine  was  found  to  block  SARS-CoV-2  infection  at  low-micromolar concentration, with a half-maximal effective concentration  (EC50) of 1.13 μM and a half-cytotoxic concentration  (CC50) greater than 100 μM (8).",
      "key": "eb97f44d936aba7ec2d09df7e04a5986",
      "line": 223,
      "object": {
        "modifier": "Activity"
      },
      "relation": "association",
      "source": 32,
      "target": 9
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Lopinavir/ritonavir is  a  medication  for  the  human  immunodeficiency  virus  (HIV)  used  in  combination  with  other  medications  to  treat  adults  and  children  over  14  days  of  age  who  are  infected with HIV-1 (5). Chu et al. found that lopinavir/ritonavir  has  anti-SARS-CoV  activity  in  vitro  and  in  clinical  studies  (6).",
      "key": "32ffcb243fa3a5bc6d210cb0103ad861",
      "line": 211,
      "relation": "negativeCorrelation",
      "source": 65,
      "target": 73
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Lopinavir/ritonavir is  a  medication  for  the  human  immunodeficiency  virus  (HIV)  used  in  combination  with  other  medications  to  treat  adults  and  children  over  14  days  of  age  who  are  infected with HIV-1 (5). Chu et al. found that lopinavir/ritonavir  has  anti-SARS-CoV  activity  in  vitro  and  in  clinical  studies  (6).",
      "key": "3c61836ee2d3d9ea6cffec4d8c221f9b",
      "line": 212,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 65,
      "target": 35
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Ribavirin  is  a  nucleoside  analogue  with  a  broad-spectrum  of  antiviral  effects.  A  study  compared  111  patients  with  severe  acute  respiratory  syndrome  (SARS)  treated  with  ribavirin  monotherapy  and  41  patients  with  SARS  treated  with  lopinavir/ritonavir and ribavirin; patients treated with the combined therapy  had  a  lower  risk  of  acute  respiratory  distress  syndrome  (ARDS)  and  death  (6).",
      "key": "424d9aa3ec82549a4962480a45f0446c",
      "line": 218,
      "relation": "decreases",
      "source": 65,
      "target": 76
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Ribavirin  is  a  nucleoside  analogue  with  a  broad-spectrum  of  antiviral  effects.  A  study  compared  111  patients  with  severe  acute  respiratory  syndrome  (SARS)  treated  with  ribavirin  monotherapy  and  41  patients  with  SARS  treated  with  lopinavir/ritonavir and ribavirin; patients treated with the combined therapy  had  a  lower  risk  of  acute  respiratory  distress  syndrome  (ARDS)  and  death  (6).",
      "key": "7f0133564619a658c46db45914838be6",
      "line": 219,
      "relation": "decreases",
      "source": 65,
      "target": 88
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Lopinavir/ritonavir is  a  medication  for  the  human  immunodeficiency  virus  (HIV)  used  in  combination  with  other  medications  to  treat  adults  and  children  over  14  days  of  age  who  are  infected with HIV-1 (5). Chu et al. found that lopinavir/ritonavir  has  anti-SARS-CoV  activity  in  vitro  and  in  clinical  studies  (6).",
      "key": "8db0891e711d0b5e2b959bcc205f4689",
      "line": 211,
      "relation": "negativeCorrelation",
      "source": 73,
      "target": 65
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Arbidol  is  an  antiviral  that  can  be  used  to  treat  influenza  virus.  A  study  has  revealed  that  arbidol  can  effectively  inhibit  SARS-CoV-2 infection at a concentration of 10-30 μM in vitro (9).",
      "key": "1faa16281eda555eb2bb15814a3e994d",
      "line": 228,
      "relation": "isA",
      "source": 25,
      "target": 32
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Arbidol  is  an  antiviral  that  can  be  used  to  treat  influenza  virus.  A  study  has  revealed  that  arbidol  can  effectively  inhibit  SARS-CoV-2 infection at a concentration of 10-30 μM in vitro (9).",
      "key": "3e9b57dc82f604d93cbd7bef18bb8a72",
      "line": 229,
      "relation": "negativeCorrelation",
      "source": 25,
      "target": 77
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Arbidol  is  an  antiviral  that  can  be  used  to  treat  influenza  virus.  A  study  has  revealed  that  arbidol  can  effectively  inhibit  SARS-CoV-2 infection at a concentration of 10-30 μM in vitro (9).",
      "key": "418431a8d13ee3ef282f8ca734826275",
      "line": 230,
      "relation": "decreases",
      "source": 25,
      "target": 71
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Arbidol  is  an  antiviral  that  can  be  used  to  treat  influenza  virus.  A  study  has  revealed  that  arbidol  can  effectively  inhibit  SARS-CoV-2 infection at a concentration of 10-30 μM in vitro (9).",
      "key": "577ca8392f753e879a2361df91c0e714",
      "line": 229,
      "relation": "negativeCorrelation",
      "source": 77,
      "target": 25
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza  virus  activity,  favipiravir  is  capable  of  blocking  the  replication  of  flavi-,  alpha-,  filo-,  bunya-,  arena-, noro-, and other RNA viruses (10).",
      "key": "f4c1c64421c2bc712cb6a740c35084b7",
      "line": 234,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 77,
      "target": 14
    },
    {
      "key": "b2c5e932804f88a21efc7c8599fbc875",
      "relation": "partOf",
      "source": 34,
      "target": 63
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza  virus  activity,  favipiravir  is  capable  of  blocking  the  replication  of  flavi-,  alpha-,  filo-,  bunya-,  arena-, noro-, and other RNA viruses (10).",
      "key": "54b02f7fd8b8f8d5d406f5cfb3c8652a",
      "line": 235,
      "relation": "negativeCorrelation",
      "source": 83,
      "target": 14
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza  virus  activity,  favipiravir  is  capable  of  blocking  the  replication  of  flavi-,  alpha-,  filo-,  bunya-,  arena-, noro-, and other RNA viruses (10).",
      "key": "63975e4e0006de652fed99fc3bbb6b48",
      "line": 236,
      "relation": "negativeCorrelation",
      "source": 78,
      "target": 14
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza  virus  activity,  favipiravir  is  capable  of  blocking  the  replication  of  flavi-,  alpha-,  filo-,  bunya-,  arena-, noro-, and other RNA viruses (10).",
      "key": "470390c93d804763556f3f1fe52c7b14",
      "line": 237,
      "relation": "negativeCorrelation",
      "source": 82,
      "target": 14
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza  virus  activity,  favipiravir  is  capable  of  blocking  the  replication  of  flavi-,  alpha-,  filo-,  bunya-,  arena-, noro-, and other RNA viruses (10).",
      "key": "9f550785910231c64ead1b4392e4487a",
      "line": 238,
      "relation": "negativeCorrelation",
      "source": 80,
      "target": 14
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza  virus  activity,  favipiravir  is  capable  of  blocking  the  replication  of  flavi-,  alpha-,  filo-,  bunya-,  arena-, noro-, and other RNA viruses (10).",
      "key": "3d91822c349c187c5c6a3fb2f5ce014e",
      "line": 239,
      "relation": "negativeCorrelation",
      "source": 79,
      "target": 14
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza  virus  activity,  favipiravir  is  capable  of  blocking  the  replication  of  flavi-,  alpha-,  filo-,  bunya-,  arena-, noro-, and other RNA viruses (10).",
      "key": "46a5847b6b5d18116e26d2ecd550e774",
      "line": 240,
      "relation": "negativeCorrelation",
      "source": 81,
      "target": 14
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza  virus  activity,  favipiravir  is  capable  of  blocking  the  replication  of  flavi-,  alpha-,  filo-,  bunya-,  arena-, noro-, and other RNA viruses (10).",
      "key": "0be650c2b9ad895580da0ebc15e7d5d7",
      "line": 241,
      "relation": "negativeCorrelation",
      "source": 85,
      "target": 14
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Favipiravir  is  converted  into  an  active  phosphoribosylated  form  (favipiravir-RTP)  in  cells  and  is  recognized  as  a  substrate by viral RNA polymerase, thus inhibiting RNA polymerase activity (11).",
      "key": "b4f067851b268041b81a6c938735cdc5",
      "line": 247,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 63,
      "target": 34
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Hoffmann  et  al.  indicated  that  SARS-CoV-2  uses  the  SARS-CoV  receptor,  ACE2,  and the cellular protease TMPRSS2 to enter target cells.",
      "key": "a6ab3913549a751836131a1e15baeac4",
      "line": 275,
      "relation": "association",
      "source": 68,
      "target": 58
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Hoffmann  et  al.  indicated  that  SARS-CoV-2  uses  the  SARS-CoV  receptor,  ACE2,  and the cellular protease TMPRSS2 to enter target cells.",
      "key": "4bd9b05732c50bf5773805ff479c351e",
      "line": 275,
      "relation": "association",
      "source": 58,
      "target": 68
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "Hoffmann  et  al.  indicated  that  SARS-CoV-2  uses  the  SARS-CoV  receptor,  ACE2,  and the cellular protease TMPRSS2 to enter target cells.",
      "key": "fa37ae00b303af4ef201baa6966b6b96",
      "line": 276,
      "relation": "association",
      "source": 58,
      "target": 69
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "bda5113fc41b2b087ccd85eccf170460",
      "line": 290,
      "relation": "negativeCorrelation",
      "source": 31,
      "target": 71
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "1f98da1dcab1ff46f11e32805a668717",
      "line": 294,
      "relation": "negativeCorrelation",
      "source": 28,
      "target": 71
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "8506edf5230a0fa6841c39ba266d47b1",
      "line": 295,
      "relation": "negativeCorrelation",
      "source": 29,
      "target": 71
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "ec98ce824edcc534041be2f635f70081",
      "line": 298,
      "relation": "negativeCorrelation",
      "source": 1,
      "target": 71
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "9e52b7287b4e3f96c2c4e1b79f745bb3",
      "line": 304,
      "relation": "negativeCorrelation",
      "source": 30,
      "target": 71
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "eddbabbd8986d85dcb8cb2c3f9c00f4d",
      "line": 305,
      "relation": "negativeCorrelation",
      "source": 27,
      "target": 71
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "23e7e4d2afa721ead824f490e776aa22",
      "line": 308,
      "relation": "negativeCorrelation",
      "source": 37,
      "target": 71
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "8490daaf2f6156c50dcd79184949d660",
      "line": 309,
      "relation": "negativeCorrelation",
      "source": 39,
      "target": 71
    },
    {
      "citation": {
        "authors": [
          "Dong L",
          "Gao J",
          "Hu S"
        ],
        "date": "2020-01-01",
        "db": "PubMed",
        "db_id": "32147628",
        "db_name": "Drug discoveries &amp; therapeutics",
        "first": "Dong L",
        "last": "Gao J",
        "pages": "58-60",
        "volume": "14"
      },
      "evidence": "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). ",
      "key": "5e14baa3537871c749296832d6b53f44",
      "line": 310,
      "relation": "negativeCorrelation",
      "source": 40,
      "target": 71
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"cyclosporin A\")",
      "concept": {
        "name": "cyclosporin A",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "cf700e1a91a823baf238554fae8c8461"
    },
    {
      "bel": "a(CHEBI:\"trans-piceid\")",
      "concept": {
        "name": "trans-piceid",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "8e23e48697e5245ab9dab3920198beab"
    },
    {
      "bel": "a(CHEBI:Carmofur)",
      "concept": {
        "name": "Carmofur",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "53c1847d14440fab6864c0f2aa321753"
    },
    {
      "bel": "a(CHEBI:Shikonin)",
      "concept": {
        "name": "Shikonin",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "cca44afc361ace42ecb104d2197cf23f"
    },
    {
      "bel": "a(CHEBI:abacavir)",
      "concept": {
        "name": "abacavir",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "ff6eab27b3699dee4d276ce4be8301bf"
    },
    {
      "bel": "a(CHEBI:atazanavir)",
      "concept": {
        "name": "atazanavir",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "62e7c1c5acbe5d720e7750e3b7297d45"
    },
    {
      "bel": "a(CHEBI:bortezomib)",
      "concept": {
        "name": "bortezomib",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "1c4f1f64578d62ea01e3bb49b78d9ad0"
    },
    {
      "bel": "a(CHEBI:carfilzomib)",
      "concept": {
        "name": "carfilzomib",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "d95dd44600fc16adef2532a729e22213"
    },
    {
      "bel": "a(CHEBI:chalcone)",
      "concept": {
        "name": "chalcone",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "3260302a07e7dc152cd18e953900a1db"
    },
    {
      "bel": "a(CHEBI:chloroquine)",
      "concept": {
        "name": "chloroquine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "c368fe204031ce23a04cc402914492f6"
    },
    {
      "bel": "a(CHEBI:darunavir)",
      "concept": {
        "name": "darunavir",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "3e5b5fd80ab9fe8d31884863982f53e2"
    },
    {
      "bel": "a(CHEBI:disulfiram)",
      "concept": {
        "name": "disulfiram",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "2a8755be3d601e2aedce44338b5d66e3"
    },
    {
      "bel": "a(CHEBI:ebselen)",
      "concept": {
        "name": "ebselen",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "6a0c92d63c214f522e6a1eb29a1b12bc"
    },
    {
      "bel": "a(CHEBI:elvitegravir)",
      "concept": {
        "name": "elvitegravir",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "f15baeaaf0faa012f4c8570a87991395"
    },
    {
      "bel": "a(CHEBI:favipiravir)",
      "concept": {
        "name": "favipiravir",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "3ce0aabad27ceb19780b9fea724eecf1"
    },
    {
      "bel": "a(CHEBI:fosamprenavir)",
      "concept": {
        "name": "fosamprenavir",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "2878f1fd9191f25b033a43fabb38f60a"
    },
    {
      "bel": "a(CHEBI:imatinib)",
      "concept": {
        "name": "imatinib",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "0a4fe509b7a61a00f432c7b089523bc6"
    },
    {
      "bel": "a(CHEBI:indinavir)",
      "concept": {
        "name": "indinavir",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "a05c553d7d11f3d9f7ace67c478a39f4"
    },
    {
      "bel": "a(CHEBI:lopinavir)",
      "concept": {
        "name": "lopinavir",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "540f0a29f78ff437222f25e1c2e1b0fd"
    },
    {
      "bel": "a(CHEBI:montelukast)",
      "concept": {
        "name": "montelukast",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "1d14f24c3bf0b728415c2c92f33b7b54"
    },
    {
      "bel": "a(CHEBI:raltegravir)",
      "concept": {
        "name": "raltegravir",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "36277f82cffec267f69880fdf2614622"
    },
    {
      "bel": "a(CHEBI:ribavirin)",
      "concept": {
        "name": "ribavirin",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "c126fb0a90c3749d6b1418b349632dcb"
    },
    {
      "bel": "a(CHEBI:ritonavir)",
      "concept": {
        "name": "ritonavir",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "07c1651afef7019b0cb107f1ce5fef12"
    },
    {
      "bel": "a(CHEBI:saquinavir)",
      "concept": {
        "name": "saquinavir",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "d1807f6bedeb2b24fd5a4c91886027e5"
    },
    {
      "bel": "a(CHEBI:tipranavir)",
      "concept": {
        "name": "tipranavir",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "e561261a90d6015196abb55822c2a03d"
    },
    {
      "bel": "a(CHEBI:umifenovir)",
      "concept": {
        "name": "umifenovir",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "4b2285b93eae04cb8e4d522d829c1df1"
    },
    {
      "bel": "a(DRUGBANK:DB05258)",
      "concept": {
        "name": "DB05258",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "1cd1637378a4cb6cb23b438ff49046ef"
    },
    {
      "bel": "a(DRUGBANK:DB05448)",
      "concept": {
        "name": "DB05448",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "458f031b4dfb12a54c2d26490fa6a13f"
    },
    {
      "bel": "a(DRUGBANK:DB06234)",
      "concept": {
        "name": "DB06234",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "6e5878028589ff7c91a6a98e1735c6f3"
    },
    {
      "bel": "a(DRUGBANK:DB06817)",
      "concept": {
        "name": "DB06817",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "622576d1f75aa410057ebf77ac0fcdea"
    },
    {
      "bel": "a(DRUGBANK:DB12129)",
      "concept": {
        "name": "DB12129",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "b24dc679750c43e6db253e2f05e870a0"
    },
    {
      "bel": "a(DRUGBANK:DB12165)",
      "concept": {
        "name": "DB12165",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "a3f968ea78f417f18dba2c0a822c9589"
    },
    {
      "bel": "a(MESH:\"Antiviral Agents\")",
      "concept": {
        "name": "Antiviral Agents",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "583ff9c1822e9ca9f4e6d7306bd6c961"
    },
    {
      "bel": "a(MESH:\"HIV Protease Inhibitors\")",
      "concept": {
        "name": "HIV Protease Inhibitors",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "e605a74a19ce54cc3d12abeb56deaa26"
    },
    {
      "bel": "a(MESH:\"RNA Replicase\")",
      "concept": {
        "name": "RNA Replicase",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "59d11052c65bf27af763bf7613595c88"
    },
    {
      "bel": "a(MESH:\"SARS Virus\")",
      "concept": {
        "name": "SARS Virus",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "6145a705baca340d1f17e8e7c1d12845"
    },
    {
      "bel": "a(MESH:Antimalarials)",
      "concept": {
        "name": "Antimalarials",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "d933ae4cb98afd956a29d600ffe1d83a"
    },
    {
      "bel": "a(MESH:Cinanserin)",
      "concept": {
        "name": "Cinanserin",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "8919b7fa9ee010083c9a8939b22959a7"
    },
    {
      "bel": "a(MESH:Lung)",
      "concept": {
        "name": "Lung",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "01153b8afebc21b98ee3c9ceb2b46df9"
    },
    {
      "bel": "a(MESH:Pinellia)",
      "concept": {
        "name": "Pinellia",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "22c2042be135c2f8840cb02dfcf1cc94"
    },
    {
      "bel": "a(MESH:Sophora)",
      "concept": {
        "name": "Sophora",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "5ff3d94049471f78eec335cca746f949"
    },
    {
      "bel": "a(PUBCHEM:11313622)",
      "concept": {
        "name": "11313622",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "93d60ac7b723ca7be5377ed401200b65"
    },
    {
      "bel": "a(PUBCHEM:121304016)",
      "concept": {
        "name": "121304016",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "7704f9ea62204912dace9e0cfb704c95"
    },
    {
      "bel": "a(PUBCHEM:131411)",
      "concept": {
        "name": "131411",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "6d4ebf981187c99689b6a10f498eba7e"
    },
    {
      "bel": "a(PUBCHEM:219104)",
      "concept": {
        "name": "219104",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "268c405dfe9317f8810361bb5ada0a40"
    },
    {
      "bel": "a(PUBCHEM:347910052)",
      "concept": {
        "name": "347910052",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "4bf76319f8f73d9f96320022b17f8f37"
    },
    {
      "bel": "a(PUBCHEM:4124851)",
      "concept": {
        "name": "4124851",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "03565b54e9b918db3225e362b10bab36"
    },
    {
      "bel": "a(PUBCHEM:471161)",
      "concept": {
        "name": "471161",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "039f0e45c6c94b4de7b8f7efb334d1d6"
    },
    {
      "bel": "a(PUBCHEM:5281718)",
      "concept": {
        "name": "5281718",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "243c4cacdfe4487c0ea52c338524c044"
    },
    {
      "bel": "a(PUBCHEM:5316606)",
      "concept": {
        "name": "5316606",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "80fa27a010a9a47ab1bc17881bce70cd"
    },
    {
      "bel": "a(PUBCHEM:5475158)",
      "concept": {
        "name": "5475158",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "bccedc13a8efd4488d2329082631b555"
    },
    {
      "bel": "a(PUBCHEM:58029842)",
      "concept": {
        "name": "58029842",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "c7cb57dfe45d1482d14e8c01f45285cb"
    },
    {
      "bel": "a(PUBCHEM:58406357)",
      "concept": {
        "name": "58406357",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "9299ff3b08e75d62cf3e9876800352f7"
    },
    {
      "bel": "a(PUBCHEM:64927)",
      "concept": {
        "name": "64927",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "d1d9cd19651e6f35ce814088de31cdd1"
    },
    {
      "bel": "a(TAX:\"Human immunodeficiency virus\")",
      "concept": {
        "name": "Human immunodeficiency virus",
        "namespace": "TAX"
      },
      "function": "Abundance",
      "id": "4ffa35214e19ab07e733adf5e1f6420c"
    },
    {
      "bel": "a(TAX:\"Middle East respiratory syndrome-related coronavirus\")",
      "concept": {
        "name": "Middle East respiratory syndrome-related coronavirus",
        "namespace": "TAX"
      },
      "function": "Abundance",
      "id": "f954d5cc971a29c7e7089ca32a056914"
    },
    {
      "bel": "a(TAX:\"Severe acute respiratory syndrome coronavirus 2\")",
      "concept": {
        "name": "Severe acute respiratory syndrome coronavirus 2",
        "namespace": "TAX"
      },
      "function": "Abundance",
      "id": "c41851da59cc36c21b2e8acf24c1f46d"
    },
    {
      "bel": "a(TAX:\"Severe acute respiratory syndrome-related coronavirus\")",
      "concept": {
        "name": "Severe acute respiratory syndrome-related coronavirus",
        "namespace": "TAX"
      },
      "function": "Abundance",
      "id": "a824ba056422b4e42996cd3269ec9a19"
    },
    {
      "bel": "bp(FIXME:\"SARS-CoV-2 entry\")",
      "concept": {
        "name": "SARS-CoV-2 entry",
        "namespace": "FIXME"
      },
      "function": "BiologicalProcess",
      "id": "7e823339938e8336126041874738280f"
    },
    {
      "bel": "bp(GO:\"fusion of virus membrane with host endosome membrane\")",
      "concept": {
        "name": "fusion of virus membrane with host endosome membrane",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "fd9a8562540e1c409a18140c9d8048fd"
    },
    {
      "bel": "bp(GOBP:\"fusion of virus membrane with host endosome membrane\")",
      "concept": {
        "name": "fusion of virus membrane with host endosome membrane",
        "namespace": "GOBP"
      },
      "function": "BiologicalProcess",
      "id": "29a13cdcefdfcfd2df907e66b7d3ff80"
    },
    {
      "bel": "bp(GOBP:\"viral genome replication\")",
      "concept": {
        "name": "viral genome replication",
        "namespace": "GOBP"
      },
      "function": "BiologicalProcess",
      "id": "415c15bf0ba2750d04619d778d539428"
    },
    {
      "bel": "bp(MESHPP:\"Virus Replication\")",
      "concept": {
        "name": "Virus Replication",
        "namespace": "MESHPP"
      },
      "function": "BiologicalProcess",
      "id": "858114bf36f0f57a4194684f697eb700"
    },
    {
      "bel": "complex(a(CHEBI:favipiravir), a(MESH:\"RNA Replicase\"))",
      "function": "Complex",
      "id": "4dc8a0002455ee22c48cde2c40409f59",
      "members": [
        {
          "bel": "a(CHEBI:favipiravir)",
          "concept": {
            "name": "favipiravir",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "3ce0aabad27ceb19780b9fea724eecf1"
        },
        {
          "bel": "a(MESH:\"RNA Replicase\")",
          "concept": {
            "name": "RNA Replicase",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "59d11052c65bf27af763bf7613595c88"
        }
      ]
    },
    {
      "bel": "composite(a(CHEBI:lopinavir), a(CHEBI:ribavirin))",
      "function": "Composite",
      "id": "c59423a8e851b3f71f99a8175b6a7a13",
      "members": [
        {
          "bel": "a(CHEBI:lopinavir)",
          "concept": {
            "name": "lopinavir",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "540f0a29f78ff437222f25e1c2e1b0fd"
        },
        {
          "bel": "a(CHEBI:ribavirin)",
          "concept": {
            "name": "ribavirin",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "c126fb0a90c3749d6b1418b349632dcb"
        }
      ]
    },
    {
      "bel": "composite(a(CHEBI:lopinavir), a(CHEBI:ritonavir))",
      "function": "Composite",
      "id": "604986238aca313adcc37629dfa6e61a",
      "members": [
        {
          "bel": "a(CHEBI:lopinavir)",
          "concept": {
            "name": "lopinavir",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "540f0a29f78ff437222f25e1c2e1b0fd"
        },
        {
          "bel": "a(CHEBI:ritonavir)",
          "concept": {
            "name": "ritonavir",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "07c1651afef7019b0cb107f1ce5fef12"
        }
      ]
    },
    {
      "bel": "composite(a(CHEBI:ribavirin), a(CHEBI:ritonavir))",
      "function": "Composite",
      "id": "e39a1f5be90142169d0c6937ad0dec64",
      "members": [
        {
          "bel": "a(CHEBI:ribavirin)",
          "concept": {
            "name": "ribavirin",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "c126fb0a90c3749d6b1418b349632dcb"
        },
        {
          "bel": "a(CHEBI:ritonavir)",
          "concept": {
            "name": "ritonavir",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "07c1651afef7019b0cb107f1ce5fef12"
        }
      ]
    },
    {
      "bel": "p(HGNC:ABL1)",
      "concept": {
        "name": "ABL1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "5157428d78980cfefda4797de047b42a"
    },
    {
      "bel": "p(HGNC:ACE2)",
      "concept": {
        "name": "ACE2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "bb9a231a2c68ff8f3bad2adad9ed6a94"
    },
    {
      "bel": "p(HGNC:TMPRSS2)",
      "concept": {
        "name": "TMPRSS2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "1ac71e8152c90a7b43c9bc546579050d"
    },
    {
      "bel": "p(MESH:\"Fusion Proteins, bcr-abl\")",
      "concept": {
        "name": "Fusion Proteins, bcr-abl",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "74371013cbe7e28220b6c91974a8e5dd"
    },
    {
      "bel": "path(DO:\"COVID-19\")",
      "concept": {
        "name": "COVID-19",
        "namespace": "DO"
      },
      "function": "Pathology",
      "id": "6f9f1c2e8012537e503a758c6bfaff0f"
    },
    {
      "bel": "path(DO:\"adult respiratory distress syndrome\")",
      "concept": {
        "name": "adult respiratory distress syndrome",
        "namespace": "DO"
      },
      "function": "Pathology",
      "id": "13c578f210684ad9f22dd027aa28b11a"
    },
    {
      "bel": "path(DO:\"human immunodeficiency virus infectious disease\")",
      "concept": {
        "name": "human immunodeficiency virus infectious disease",
        "namespace": "DO"
      },
      "function": "Pathology",
      "id": "a1ed6919dd80c191ef803730caf98e2e"
    },
    {
      "bel": "path(DO:hepatitis)",
      "concept": {
        "name": "hepatitis",
        "namespace": "DO"
      },
      "function": "Pathology",
      "id": "626a7d9634cabd950f531a06490fc3f0"
    },
    {
      "bel": "path(DO:influenza)",
      "concept": {
        "name": "influenza",
        "namespace": "DO"
      },
      "function": "Pathology",
      "id": "ed15bfb63a176a38b4cce77ca70dab7a"
    },
    {
      "bel": "path(EFO:\"acute respiratory distress syndrome\")",
      "concept": {
        "name": "acute respiratory distress syndrome",
        "namespace": "EFO"
      },
      "function": "Pathology",
      "id": "f3314ef28a1a3d7c8c5d89dfe1a7fb75"
    },
    {
      "bel": "path(EFO:\"influenza infection\")",
      "concept": {
        "name": "influenza infection",
        "namespace": "EFO"
      },
      "function": "Pathology",
      "id": "0748fb9f39f60436701b652d3db6a8ee"
    },
    {
      "bel": "path(MESH:\"Alphavirus Infections\")",
      "concept": {
        "name": "Alphavirus Infections",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "504d69328670f191fac0b8ff77c1ba83"
    },
    {
      "bel": "path(MESH:\"Arenaviridae Infections\")",
      "concept": {
        "name": "Arenaviridae Infections",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "a47549cc843138e02e9d4643aee3dbaf"
    },
    {
      "bel": "path(MESH:\"Bunyaviridae Infections\")",
      "concept": {
        "name": "Bunyaviridae Infections",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "b0ae593230e6f7f14843744c0eeb15ed"
    },
    {
      "bel": "path(MESH:\"Caliciviridae Infections\")",
      "concept": {
        "name": "Caliciviridae Infections",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "e19ef834ad4f6d082ebcdd1a6b58737f"
    },
    {
      "bel": "path(MESH:\"Filoviridae Infections\")",
      "concept": {
        "name": "Filoviridae Infections",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "08446e0ede5b9b50a9610c6917a3febd"
    },
    {
      "bel": "path(MESH:\"Flavivirus Infections\")",
      "concept": {
        "name": "Flavivirus Infections",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "4fdde8325857dd021a737f5ffad6b0dd"
    },
    {
      "bel": "path(MESH:\"Lung Injury\")",
      "concept": {
        "name": "Lung Injury",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "0331236e5bff96357737ca4f300a8893"
    },
    {
      "bel": "path(MESH:\"RNA Virus Infections\")",
      "concept": {
        "name": "RNA Virus Infections",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "72c92ace426acc7ff9d4c37b7f1af480"
    },
    {
      "bel": "path(MESH:\"Viral Load\")",
      "concept": {
        "name": "Viral Load",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "6dd60f9fcfb2c325548af01a7a752ada"
    },
    {
      "bel": "path(MESH:\"Virus Replication\")",
      "concept": {
        "name": "Virus Replication",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "5e513772ef3f1f2bafe1df69ef149abc"
    },
    {
      "bel": "path(MESH:Death)",
      "concept": {
        "name": "Death",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "10a8517e414b47762b224fc2cc999027"
    }
  ]
}